In a bipartisan effort, U.S. Senators have reintroduced legislation banning a pharmaceutical industry practice that keeps lower-cost medications away from patients who need them. The practice, commonly called “pay for delay,” occurs when one drug company pays another to delay introducing a less-expensive generic version of a medication.
According to Reuters, both American and European anti-trust regulators have long criticized the practice. It recently came to the forefront again after European ...
continue reading...
In a Los Angeles Superior Court trial, an occupational medicine specialist testified that a man’s artificial hip had to be removed because of “toxic exposure” from metal debris that the implant was shedding, according to a Reuters story.
European regulators are accusing Johnson & Johnson of illegally paying another company to delay the availability of a generic version of a product – in the process denying cancer patients access to a less expensive source of a drug that eases severe pain.
A piece in The Economist ironically describes Johnson & Johnson as the “market leader” for publicity problems, based on the company’s disastrous series of product recalls in recent years.
